Publicaciones en colaboración con investigadores/as de The Bristol-Myers Squibb Children's Hospital (4)

2018

  1. Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))

    European Urology

  2. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

    New England Journal of Medicine, Vol. 378, Núm. 14, pp. 1277-1290

2017

  1. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]

    European Urology, Vol. 72, Núm. 6, pp. 962-971

2015

  1. Nivolumab versus everolimus in advanced renal-cell carcinoma

    New England Journal of Medicine, Vol. 373, Núm. 19, pp. 1803-1813